Download presentation
Presentation is loading. Please wait.
Published byAnne Conley Modified over 8 years ago
1
Managing Blood Pressure in the Older Adult Jamie McCarrell, Pharm.D., BCPS, CGP TTUHSC School of Pharmacy
2
Objectives Describe key pharmacodynamic changes that occur as we age which impact the efficacy of certain anti-hypertensive agents State current guideline recommendations for treatment of hypertension in older adults Evaluate current literature recommendations for blood pressure treatment goals in older adults Given a patient case, develop a plan for initiating, changing, and monitoring a medication regimen for hypertension.
3
MYTH Older adults have altered response to medications because they have altered ADME (pharmacokinetic) properties.
4
PHARMACODYNAMIC AND PHYSIOLOGIC CHANGES Managing Blood Pressure in the Older Adult
5
Beta-adrenergic changes beta-adrenergic receptors on myocardium beta-adrenergic response to stimulus – serum levels or noradrenalin…tachyphylaxis? Beta-blocker effects? What about HF or MI?
6
RAAS Possible decrease in ACE-inhibitor efficacy Risk of hyperkalemia due to decreased aldosterone www.mlo-online.com
7
Little Information Dihydropyridine CCBs – Will drop BP more than younger adults – No reflex tachycardia when BP drops Peripheral α-blockers – Significantly larger BP drop than younger adults with no increase in serum concentration – No reflex tachycardia when BP drops Large risk of postural hypotension with peripheral α-blockers
8
Postural Hypotension www.scimath.org
9
Isolated Systolic Hypertension Lancet 2006.
10
Pharmacokinetic Changes Phase 1 vs Phase 2 metabolism – Many common antihypertensive medications are metabolized through CYP enzymes (phase 1) – CYP enzymes can be drastically altered in older adults (number and function) – Results in clinically significant drug interactions Example: amlodipine + simvastatin – Made worse by old age??
11
TREATMENT – JNC 8 Managing Blood Pressure in the Older Adult
12
Committee Recommendations Recommendation #1 – General patient age 60+, use goal BP 150/90 – Corollary: If on therapy and SBP is < 140 with NO adverse effects, continue therapy as is (don’t back off) Recommendation #2 – General patient age < 60, use diastolic BP goal of < 90 – Age 18-29 is “expert opinion”
13
Committee Recommendations Recommendation #3 – For general patient < 60, use systolic BP goal of < 140 – Expert opinion for whole group Recommendation #4 – For patients 18+ with CKD, use BP goal < 140/90 – How defined? – What about geriatrics?
14
Committee Recommendations Recommendation #5 – In patients 18+ with diabetes, use BP goal < 140/90 Recommendation #6 – For non-black patients, initial therapy should be one of the following agents (any) Thiazide-type diuretic ACE inhibitor ARB CCB
15
Committee Recommendations Recommendation #7 – For a black patient, initial therapy should be selected from the following: Thiazide-type diuretic CCB Recommendation #8 – For patients age 18+ with CKD, the initial therapy should be an ACE or ARB Can add ACE or ARB to gain renal outcome benefit
16
Committee Recommendations Recommendation #9 – Treat to the goals…if not there after one month, maximally titrate the agent – Still not there…add and titrate a second agent as needed – Third verse, same as the first (and second) – If still not at goal, consider an additional agent not on the recommended first line list – Don’t combine an ACE and an ARB
17
JNC 8, Renal Dysfunction, and age > 60 Two JNC 8 statements – For age > 60, use goal 150/90 – For CKD, use goal 140/90 – How do you define CKD? Age < 70 with measured or calculated GFR < 60 ml/min/1.73m 2 Any age with albuminuria
18
JNC 8, Renal Dysfunction, and age > 60 What about age > 70? – If GFR is > 60, use 150/90 (unless DM) – If GFR is < 60… “The panel cannot make a recommendation for a BP goal for people aged 70 years or older with GFR less than 60…” “Thus, when weighing the risks and benefits of a lower BP goal for people aged 70 years or older…antihypertensive treatment should be individualized, taking into account frailty, comorbidities, and albuminuria.”
19
JNC 8, Renal Dysfunction, and age > 60
20
Old-old Systolic Goals JAGS. 2001.
21
HTN and survival in elderly men J Am Geriatr Soc 2001;49:367-74
22
HTN and survival in elderly women J Am Geriatr Soc 2001;49:367-74
23
SPRINT Trial NEJM late 2015 Tested SBP goal of 140 vs 120 Intensive treatment group had: – Less composite CV outcomes – Less individual outcomes for: HF Death from CV causes Death from any cause – More conversion to renal insufficiency (HR 3.49)
24
SPRINT Trial Limitations Mean age 67 with only 28% 75+ DIABETES! STROKE! Adverse events – all worse in intensive tx – Hypotension – Syncope – Electrolyte abnormalities – Acute kidney injury/failure
25
CHOOSING AN AGENT Managing Blood Pressure in the Older Adult
26
First line agents ACEs/ARBs – Generally well tolerated – Possibly reduced efficacy in older adults – Regular electrolyte measurements – Think about pill burden…daily is better than BID CCBs – Likely best “bang for your buck” in older adults – Dihydropyridine only (no verapamil/diltiazem) – Caution in HF…amlodipine may be agent of choice
27
First line agents Thiazide diuretics – HCTZ most common – Good BP-lowering – Caution with timing Risk of falls with frequent/late trips to restroom – Monitor electrolytes closely – Monitor for dehydration – TRIPLE WHAMMY
29
Beta blockers Still have a place in therapy – Post MI – Heart failure – Atrial fibrillation – Caution in diabetes…why? – Bradycardia risk, esp if already lower HR (older adults) – Don’t expect great BP reduction
30
Suboptimal therapies Alpha blockers – Terazosin, prazosin, doxazosin – Significant risk of hypotension – Significant risk of dizziness, falls, fractures – Should not be used for BPH unless using a prostate-specific agent (typically tamsulosin)
31
Suboptimal therapies Clonidine – Alpha-2 agonist centrally – Reduces sympathetic vasoconstriction – Significant risk of hypotension – Significant risk of dizziness and falls – Causes somnolence/sedation
32
PATIENT CASE Managing Blood Pressure in the Older Adult
33
Jamie McCarrell, Pharm.D., BCPS, CGP TTUHSC School of Pharmacy
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.